Slingshot Insights

Catalyst

Slingshot members are tracking this event:

Ionis Pharma (IONS) expects to report on Phase 3 study of ISIS-TTR Rx (ISIS 420915) in Patients with Familial Amyloid Polyneuropathy in early 2017

Source Link:: https://clinicaltrials.gov/ct2/show/NCT01737398?term=Ionis+Pharmaceutical&recr=Open&no_unk=Y&rank=10

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies

Importance

High

Medium

Low

Impact on Stocks

IONS

100%

SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Additional Relevant Details See IONIS-TTR for more information on the link below

http://www.ionisphar...

Additional Relevant Details Update on May 15, 2017: Over the 15-month period of the study, inotersen-treated patients achieved statistically significant benefit compared to placebo in the modified Neuropathy Impairment Score +7 (mNIS+7) and the Norfolk Quality of Life Questionnaire-Diabetic Neuropathy (Norfolk QoL-DN) (p<0.0001 and p=0.0006, respectively). Statistically significant differences were also observed for both endpoints at eight months.

http://ir.ionispharm...

Slingshot Insights Explained

JOIN FOR FREE TODAY

Catalyst Date

Occurred on:

May 15, 2017

Occurred Source:

http://ir.ionispharma.com/phoenix.zhtml?c=222170&p=irol-newsArticle&ID=2272828

Related Projects

Don’t see a project related to the catalyst you care about?

Related Keywords Phase 3 Study, Familial Amyloidotic Polyneuropathy, Familial Amyloid Polyneuropathy, Isis-ttr Rx, Isis 420915